Introduction
Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which is observed in more than 95% of CML patients. This chromosome is the result of a reciprocal translocation t(9:22)(q34;q11), which juxtaposes the 3Ј DNA sequences of the abl gene mapping on 9q34.1 with the 5Ј DNA sequences of the bcr gene mapping on 22q11.
Studies using various markers have shown that CML is a clonal neoplasm that involves a multipotent progenitor cell capable of lymphoid as well as myeloid differentiation. [1] [2] [3] The genes for glucose-6-phosphate dehydrogenase (G6PD), phosphoglycerate kinase, hypoxanthine phosphoribosyltransferase (HPRT), M27␤ and human androgen receptor are located on the X chromosome, which undergoes random inactivation during early embryogenesis in each somatic cell in females, and thus the DNAs or their products have been used for the clonal analysis of CML. 4 Clonal analysis using these genes or their products, however, is limited to samples only with a homogenous leukemia cell population. On the other hand, in individuals with the mosaic form of Turner or Klinefelter syndrome, cytogenetic analysis can distinguish different cell populations with XX and Xc cells or XXY and XY cells, respectively. Thus, in rare individuals with both CML and such a constitutional chromosome mosaicism, the clonality of CML is visually clarified.
In a unique case of CML arising as a clone in the monosomic (45, Xc) cells in a 27-year-old patient with Turner syndrome mosaic, extensive cytogenetic studies at diagnosis, including triple color fluorescence in situ hybridization (FISH), showed that Ph-positive monosomic leukemia cells predominated, with a few Ph-negative monosomic and normal diploid (46, XX) cells. The cytogenetic studies that were subsequently performed over a period of 31 months revealed that Ph-negative monosomic cells and normal diploid cells recovered in response to therapy with human lymphoblastoid interferon-␣ (IFN-␣). Moreover, this unique case revealed a survival advantage of CML cells as well as a different propotion of monosomic cells among different tissues.
Materials and methods

Patient
A 27-year-old Japanese female was in good health until August 1995 when she noticed general fatigue and hypermenorrhea. She was short (140 cm tall, 43.5 kg), with normal development of breasts and external genitalia. None of the extroverted elbow, shield-like chest and other somatic features that are usually associated with Turner syndrome was present. She attained menarche at the age of 12 and had no abnormality in serum LH, FSH, progesterone and estrogen levels. Liver measured 2 cm below the costal margins but spleen was not palpable. Red blood cell (RBC) count was 4.74 × 10 12 /l, hemoglobin was 11.5 g/dl, platelet count was 438 × 10 9 /l, and white blood cell (WBC) count was 13 × 10 9 /l, with 60% segments, 2% bands, 2% eosinophils, 2% metamyelocytes, 5% myelocytes and 19% lymphocytes. Neutrophil alkaline phosphatase (NAP) score was low at 93 (normal control, 273). Bone marrow was hypercellular. A diagnosis of CML and Turner syndrome mosaic was made by the detection of the Ph chromosome in bone marrow cells and by the loss of an X chromosome in bone marrow cells and in fibroblasts from a skin biopsy specimen. Following initial treatment with hydroxyurea, IFN-␣ (600 IU/day) was started on 14 November 1995. Details of the hematologic and cytogenetic data are presented in Table 1 . On 22 January 1996, a hematologic remission was achieved and on 11 August 1997, a complete cytogenetic response was obtained, which have been maintained up to now with continuing IFN-␣ therapy. 
Karyotyping
Karyotyping was performed on air-dried preparations stained with quinacrine dihydrochroride to produce G-banding. We made every effort to perform karyotyping on 100 bone marrow cells and 100 dermal fibroblasts. Bone marrow cells were cultured for 72 h in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) (Gibco BRL, Grand Island, NY, USA). The fibroblasts from a skin biopsy specimen were cultured for 17 days in MEM (Gibco BRL) supplemented with 10% FCS.
FISH
LSI bcr-abl translocation (VYSIS, Downers Grove, IL, USA), the fluorescent spectra of which were green and orange, was detected in both major and minor breakpoint cluster regions. 5 CEP X (VYSIS), with a fluorescent spectrum of aqua, was detected in ␣ satellite region (Xp11.1-q11.1) of the centromere of the X chromosome. Air-dried preparations were prepared from bone marrow cells and fibroblasts without culture.
Overnight hybridization was performed with a mixture of LSI bcr-abl translocation and CEP X. After washing, cells were analyzed with an epifluorescence microscope (Nikon, Tokyo, Japan) equipped with a triple band-pass filter for simultaneous visualization of DAPI, green and orange fluorescence and a dual band-pass filter for aqua and orange fluorescence. One thousand nuclei were counted for the loss of the X chromosome and for the reciprocal translocation between chromosomes 9 and 22. (Table 1) . Undoubtedly, the Ph-negative cells recovered following the selective suppression of the Ph-positive leukemia clone by IFN-␣ treatment. Ph-positive cells became undetectable by both karyotyping and FISH studies on 11 August 1997, and a complete cytogenetic remission was achieved. The ratios of Xc to XX cells by karyotyping among bone marrow cells and among cultured skin fibroblasts were 97/3 and 71/29, respectively, on 11 August 1997. These ratios were significantly different (P = 0.0088 by the chi-square test).
Discussion
The association between a constitutional chromosomal imbalance and predisposition to neoplastic disease is well known. Down syndrome children have an increased incidence of myeloid leukemia. 6 In Turner syndrome, a higher incidence of neurogenic tumors has been observed. 7 With regard to hematological neoplasms in Turner syndrome, four cases of acute myeloid leukemia, one case of acute lymphoblastic leukemia, one case of chronic lymphoblastic leukemia and two cases of CML have been reported. [8] [9] [10] [11] [12] [13] [14] [15] It is difficult to conclude whether persons with Turner syndrome are prone to develop CML, since only three cases have been reported, including ours. However, in two previously reported cases, as well as our present case, leukemogenesis of CML has been restricted to the sex chromosomally abnormal clone. [12] [13] [14] Therefore, the abnormal clone of a Turner syndrome mosaic may be prone to a reciprocal translocation between chromosomes 9 and 22. On the other hand, the loss of the X chromosome is often one of the additional chromosomal aberrations in CML, 16 although its biological significance is controversial. Therefore, the loss of the X chromosome and the reciprocal translocation between chromosomes 9 and 22 may possibly have some relationship.
G-6-PD isoenzymes and the polymorphisms at the HPRT gene locus have mostly been used to show the clonal cell origin of CML. [1] [2] [3] These methods are reliably informative, but have some disadvantages. First, inclined intrinsic X chromosome inactivation pattern was recognized in normal females. 17 Second, acquired skewing occurs with aging in normal females and is present in about 38% of females over the age of 60. 18 Therefore, the simultaneous demonstration of clonality and bcr rearrangements in CML by these methods does not answer the question of whether these two findings result from events that occur concomitantly or sequentially. 2 However, our cytogenetic studies, including triple color FISH before and during the IFN-␣ therapy, have resolved this question. Monoclonality and bcr rearrangements in CML occur concomitantly.
Recovery of polyclonal hematopoiesis was demonstrated using the BstXI PGK gene polymorphism in interferon-induced cytogenetic remissions of CML. 19 However, the native imbalance and the acquired skewing of the X chromosome often obscure the results of studies of clonality by this method. Our data clearly demonstrated that monosomic non-leukemia cells and normal diploid cells were present in the marrow of this patient at diagnosis and expanded following the selective suppression of the leukemia clone by successful IFN-␣ therapy. IFN-␣ appeared to eradicate the CML clone selectively.
The percentage of Xc cells was significantly different between bone marrow cells and skin fibroblasts. The percentage of Xc cells was 71% in skin fibroblasts, but 94 to 97% in bone marrow cells (Table 1) . Gale et al 20 reported, using differential methylation patterns for PGK, M27␤ and HPRT, that patterns of X chromosome inactivation differed among tissues. Our data additionally show that the proportion of the monosomic cells differs between tissues. This fact demonstrates the difficulty of the interpretation of clonality in individual tumor samples and emphasizes the importance of comparison between malignant and non-malignant cells in the same tissue.
Another very interesting observation in this rare case is that, at diagnosis and about 1 month after the start of IFN-␣ therapy, while the ratio of whole Xc cells, regardless of the presence of Ph to XX cells in bone marrow was almost the same between karyotyping and FISH analysis, the ratio of t (9; higher in FISH analyses. Since this patient was diagnosed at a rather early stage of CML when her peripheral blood WBC count was 13 × 10 9 /l, we might have concluded that only 40% of marrow cells were of leukemia origin when we analyzed t(9;22) only by karyotyping. However, actually around 80% of her bone marrow cells were of leukemia origin by FISH analysis. One might explain this discrepancy by the sensitivity of those two analyses. FISH analysis is generally regarded as a more sensitive method for the identification of details of chromosomal abnormality, such as t(9;22), than conventional karyotyping. 21 However, if this is true, this should also apply to the loss of the X chromosome, since CML in this patient occurred in the monoclonal cells with the loss of one X chromosome. The fact was that the loss of one X chromosome was equally detected by both karyotyping and FISH analysis.
Another explanation is that karyotyping detects chromosomal abnormality of cells only in metaphase but FISH analysis detects that of cells in both metaphase and interphase. However, this should also have applied to analyses during cytogenetic remission in this patient. The fact was that the ratios of Xc cells to XX cells were almost the same in both analyses during remission. The data thus indicated that leukemia cells in interphase unproportionally expanded in this patient before IFN-␣ therapy. Therefore, another explanation is needed. We believe that this unique case supports the hypothesis that the BCR/ABL transcripts provide a survival advantage for leukemia cells including mature neutrophils, rendering them more resistant to apoptosis. 22 There are several reports demonstrating that apoptosis is inhibited in vitro in cell lines expressing p210 bcr/abl , in v-abl-transfected cells as well as in progenitors and granulocytes obtained directly from CML patients, and that the reduced programmed cell death is attributed to the primary mechanism responsible for expansion of the leukemia clone in CML. [22] [23] [24] [25] Our extensive cytogenetic analysis by both karyotyping and FISH analysis supports these interpretations from another point of view.
Studies of this quite unique case resulted in several important findings. First, the monoclonality of CML was clearly demonstrated. Second, IFN-␣ selectively suppressed this monoclonal BCR/ABL-positive leukemia clone, and subsequently, those normal diploid cells that had persisted expanded and enabled the reconstitution of normal hematopoiesis. Third, the proportion of monosomic cells is different between tissues. Fourth, the discrepant increase of the BCR/ABL-positive clone supports the hypothesis that reduced programmed cell death may be the primary mechanism responsible for the expansion of the leukemia clone in CML. Finally, this study emphasizes the importance of extensive analysis of a neoplastic disease in patients with a constitutional chromosomal abnormality.
